[{"article_id":38,"discovery_date":"2018-11-01","title":"Reduction of the risk of PML in natalizumab treated MS patients in Sweden: An effect of improved PML risk surveillance","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 11;50:102842. doi: 10.1016&#x2F;j.msard.2021.102842. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Natalizumab (NTZ) treatment of multiple sclerosis (MS) has been associated with increased risk of progressive multifocal leukoencephalopathy (PML). The aim of the present study was to evaluate the impact of PML risk assessment on PML incidence in NTZ treated MS patients.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: By using information from the population-based Swedish MS registry a retrospective cohort was established of patients treated with NTZ between 2006-2018. The effect on PML incidence before and after utilizing a risk management plan, including JC virus (JCV) serology, was analyzed.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: In December 2018, 804 PML cases associated with NTZ therapy of MS had been reported globally, including 9 cases from Sweden. The estimated PML incidence 2018 in Sweden and globally was 0.7 (0.3-1.4) and 4.15 (3.9-4.4) per 1,000 person years, respectively. In Sweden, JCV serology was introduced 2012 for PML risk assessment and the cumulative risk of PML was significantly lower 2012-2018 compared to the period 2006-2011 (p&#x3D;0.042). The mean NTZ exposure time was 60.1 months (SD 37.2) in the first period (2006-2011) and 32.6 months (SD 22.0) in the second period (2012-2018). The number of patients treated with NTZ decreased, and the number of patients at increased risk of PML was 1.9 % at the end of the study period.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Since 2006 the incidence of PML associated with NTZ treatment of MS has decreased in Sweden. Our findings suggest that this reduction is due to an effective adoptation and adherence to the established risk management plan that implies switching patients at increased PML risk from NTZ to other highly efficacious therapies. A less pronounced decline in PML incidence has recently been observed in France, but not globally.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33610957&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210222032229&amp;v&#x3D;2.14.2&quot;&gt;33610957&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102842&gt;10.1016&#x2F;j.msard.2021.102842&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33610957&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210222032229&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":37,"discovery_date":"2018-11-01","title":"Tissue plasminogen activator worsens experimental autoimmune encephalomyelitis by complementary actions on lymphoid and myeloid cell responses","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neuroinflammation. 2021 Feb 20;18(1):52. doi: 10.1186&#x2F;s12974-021-02102-5.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Tissue plasminogen activator (tPA) is a serine protease involved in fibrinolysis. It is released by endothelial cells, but also expressed by neurons and glial cells in the central nervous system (CNS). Interestingly, this enzyme also contributes to pathological processes in the CNS such as neuroinflammation by activating microglia and increasing blood-brain barrier permeability. Nevertheless, its role in the control of adaptive and innate immune response remains poorly understood.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: tPA effects on myeloid and lymphoid cell response were studied in vivo in the mouse model of multiple sclerosis experimental autoimmune encephalomyelitis and in vitro in splenocytes.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: tPA&lt;sup&gt;-&#x2F;-&lt;&#x2F;sup&gt; animals exhibited less severe experimental autoimmune encephalomyelitis than their wild-type counterparts. This was accompanied by a reduction in both lymphoid and myeloid cell populations in the spinal cord parenchyma. In parallel, tPA increased T cell activation and proliferation, as well as cytokine production by a protease-dependent mechanism and via plasmin generation. In addition, tPA directly raised the expression of MHC-II and the co-stimulatory molecules CD80 and CD86 at the surface of dendritic cells and macrophages by a direct action dependent of the activation of epidermal growth factor receptor.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Our study provides new insights into the mechanisms responsible for the harmful functions of tPA in multiple sclerosis and its animal models: tPA promotes the proliferation and activation of both lymphoid and myeloid populations by distinct, though complementary, mechanisms.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33610187&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210222032229&amp;v&#x3D;2.14.2&quot;&gt;33610187&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1186&#x2F;s12974-021-02102-5&gt;10.1186&#x2F;s12974-021-02102-5&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33610187&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210222032229&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":36,"discovery_date":"2018-11-01","title":"Clinical course of central nervous system demyelinating neurological adverse events associated with anti-TNF therapy","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neurol. 2021 Feb 20. doi: 10.1007&#x2F;s00415-021-10460-6. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Previous studies have reported an association between anti-tumor necrosis factor alpha (anti-TNFα) treatment and central nervous system (CNS) events. We described eight patients presenting with demyelinating CNS events while on treatment with anti-TNFα for autoimmune diseases and followed up for a medium period of 4 years. Four patients presented with isolated demyelinating events, three patients fulfilled the criteria for multiple sclerosis (MS), and one patient showed worsening of pre-existing MS after anti-TNF therapy initiation. All patients except one, showed a good medium-term prognosis. Our observation supports an association between anti-TNFα treatment and demyelinating events and suggests that a prompt discontinuation of the drug may lead to a favorable demyelinating disease outcome.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33611609&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210222032229&amp;v&#x3D;2.14.2&quot;&gt;33611609&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s00415-021-10460-6&gt;10.1007&#x2F;s00415-021-10460-6&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33611609&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210222032229&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":35,"discovery_date":"2018-11-01","title":"Functional neurological disorder and multiple sclerosis: a systematic review of misdiagnosis and clinical overlap","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neurol. 2021 Feb 21. doi: 10.1007&#x2F;s00415-021-10436-6. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Multiple sclerosis (MS) and functional neurological disorder (FND) are both diagnostically challenging conditions which can present with similar symptoms. We systematically reviewed the literature to identify patients with MS who were misdiagnosed with FND, patients with FND who were misdiagnosed with MS, and reports of patients with both conditions. In addition to FND, we included studies of patients with other functional and psychiatric disorders where these caused symptoms leading to investigation for or a diagnosis of MS, which in a different context would likely have been labeled as FND. Our review suggests that MS is one of the most common causes of misdiagnosis of FND and vice versa. We discuss the clinical errors that appear to result in misdiagnoses, such as over-reliance on psychiatric comorbidity when making a diagnosis of FND or over-reliance on neuroimaging for the diagnosis of MS, and practical ways to avoid them. Comorbidity between these two conditions is also likely common, has been poorly studied, and adds complexity to diagnosis and treatment in patients with both MS and FND. Misdiagnosis and comorbidity in a landscape of emerging evidence-based treatments for both MS and FND are issues not only of clinical importance to the care of these patients, but also to treatment trials, especially of MS, where FND could be a hidden confounder.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33611631&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210222032229&amp;v&#x3D;2.14.2&quot;&gt;33611631&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s00415-021-10436-6&gt;10.1007&#x2F;s00415-021-10436-6&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33611631&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210222032229&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":34,"discovery_date":"2018-11-01","title":"COVID-19 in multiple sclerosis patients treated with dimethyl fumarate","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neurol. 2021 Feb 20. doi: 10.1007&#x2F;s00415-021-10446-4. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33611610&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210222032229&amp;v&#x3D;2.14.2&quot;&gt;33611610&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s00415-021-10446-4&gt;10.1007&#x2F;s00415-021-10446-4&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33611610&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210222032229&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":33,"discovery_date":"2018-11-01","title":"Efficacy of Gamma Knife radiosurgery in the management of multiple sclerosis-related trigeminal neuralgia: a systematic review and meta-analysis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurosurg Rev. 2021 Feb 20. doi: 10.1007&#x2F;s10143-021-01507-3. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Trigeminal neuralgia (TN) is the most frequent craniofacial pain condition, which commonly affects patients suffering from multiple sclerosis (MS). Stereotactic radiosurgery, especially Gamma Knife radiosurgery (GKRS), represents a safe and effective treatment for TN, and it has been adopted also for MS-TN, with a lower success rate. Therefore, we aimed to analyze the outcome of GKRS for MS-TN. PubMed, Web of Science, and Google Scholar and the reference list of relevant articles were searched for GKRS in MS-TN. Two investigators independently identified the articles, assessed the study quality, and extracted the data. Endpoints of interest were initial pain responders, successful treatments at the end of follow-up, and factors influencing the outcome. Data analyses were performed using R software. Twelve articles involving 646 patients met our inclusion criteria. Pooled proportion of patients who experienced an initial response to GKRS treatment was 83% (CI 74-90%). The cumulative proportion of successful treatments at the end of follow-up was 47% (CI 33-60%). No variables were found to have a significant contribution to heterogeneity regarding the initial response outcome. The only variable significantly explaining the heterogeneity found in the proportion of successful treatments was the length of the follow-up, with a negative b coefficient (- 0.0051, p value &#x3D; 0.0047). Regarding the efficacy of GKRS in MS-TN, the initial pain response rate was 83%, which dramatically decreases to 47% during follow-up. GKRS still represents a valuable option for MS-TN; however, its long-term efficacy should be always considered.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33611721&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210222032229&amp;v&#x3D;2.14.2&quot;&gt;33611721&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s10143-021-01507-3&gt;10.1007&#x2F;s10143-021-01507-3&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33611721&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210222032229&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":32,"discovery_date":"2018-11-01","title":"Blood Trace Element Status in Multiple Sclerosis: a Systematic Review and Meta-analysis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Biol Trace Elem Res. 2021 Feb 21. doi: 10.1007&#x2F;s12011-021-02621-5. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The aim of this meta-analysis was to investigate whether the blood concentrations of patients with multiple sclerosis (MS) are associated with those of the healthy control group in terms of trace elements including zinc (Zn), iron (Fe), manganese (Mn), magnesium (Mg), selenium (Se), and copper (Cu). A comprehensive search was performed in online databases including PubMed, Scopus, Embase, and Web of Science for studies, which have addressed trace elements in MS up to July 23, 2020. The chi-square test and I&lt;sup&gt;2&lt;&#x2F;sup&gt; statistic were utilized to evaluate inter-study heterogeneity across the included studies. Weighted mean differences (WMDs) and corresponding 95% CI were considered as a pooled effect size (ES). Twenty-seven articles (or 32 studies) with a total sample comprised of 2895 participants (MS patients (n &#x3D; 1567) and controls (n &#x3D; 1328)) were included. Pooled results using random-effects model indicated that the levels of Zn (WMD &#x3D; - 7.83 mcg&#x2F;dl, 95% CI &#x3D; - 12.78 to - 2.87, Z &#x3D; 3.09, P &#x3D; 0.002), and Fe (WMD &#x3D; - 13.66 mcg&#x2F;dl, 95% CI &#x3D; - 23.13 to - 4.19, Z &#x3D; 2.83, P &#x3D; 0.005) were significantly lower in MS patients than in controls. However, it was found that levels of Mn (WMD &#x3D; 0.03 mcg&#x2F;dl, 95% CI &#x3D; 0.01 to 0.04, Z &#x3D; 2.89, P &#x3D; 0.004) were significantly higher in MS patients. Yet, no significant differences were observed in the levels of Mg, Se, and Cu between both groups. This meta-analysis revealed that the circulating levels of Zn and Fe were significantly lower in MS patients and that Mn level was significantly higher than those in the control group. However, it was found that there was no significant difference between MS patients and controls with regard to levels of Mg, Se, and Cu.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33611740&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210222032229&amp;v&#x3D;2.14.2&quot;&gt;33611740&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s12011-021-02621-5&gt;10.1007&#x2F;s12011-021-02621-5&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33611740&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210222032229&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":31,"discovery_date":"2018-11-01","title":"Tumor Necrosis Factor Inhibition and Parkinson Disease: A Mendelian Randomization Study","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neurology. 2021 Feb 19:10.1212&#x2F;WNL.0000000000011630. doi: 10.1212&#x2F;WNL.0000000000011630. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To evaluate the effects of long-term tumor necrosis factor (TNF) inhibition on the risk and age at onset of Parkinson disease (PD), we performed a two-sample Mendelian randomization study using genome-wide association studies (GWAS) summary statistics.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Genetic variants in the vicinity of &lt;i&gt;TNFRSF1A&lt;&#x2F;i&gt;, the gene encoding TNF receptor 1 (TNFR1), were identified as predictive of pharmacologic blockade of TNFR1 signaling by anti-TNF therapy, based on genetic associations with lower circulating C-reactive protein (CRP; GWAS N &#x3D; 204,402). The effects of TNF-TNFR1 inhibition were estimated for PD risk (N&lt;sub&gt;cases&lt;&#x2F;sub&gt;&#x2F;&lt;sub&gt;controls&lt;&#x2F;sub&gt; &#x3D; 37,688&#x2F;981,372) and age at PD onset (N &#x3D; 28,568) using GWAS data from the International Parkinson&#39;s Disease Genomics Consortium and 23andMe, Inc. To validate variants as proxies of long-term anti-TNF treatment, we also assessed whether variant associations reflected anticipated effects of TNFR1 inhibition on Crohn disease, ulcerative colitis and multiple sclerosis risk (N &#x3D; 38,589-45,975).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: TNF-TNFR1 signaling inhibition was not estimated to affect PD risk (odds ratio&#x2F;OR per 10% lower circulating CRP &#x3D; 0.99; 95% CI: 0.91-1.08) or age at onset (0.13 years later onset; 95% CI: -0.66 to 0.92). In contrast, genetically-indexed TNF-TNFR1 signaling blockade predicted reduced risk of Crohn disease (OR &#x3D; 0.75; 95% CI: 0.65-0.86) and ulcerative colitis (OR &#x3D; 0.84; 95% CI: 0.74-0.97) and increased multiple sclerosis risk (OR &#x3D; 1.57; 95% CI: 1.36-1.81). Findings were consistent across models using different genetic instruments and MR estimators.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Our findings do not imply that TNF-TNFR1 signaling inhibition will prevent or delay PD onset.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that TNF-TNFR1 signaling inhibition is not associated with the risk or age at onset of PD.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33608417&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2&quot;&gt;33608417&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1212&#x2F;WNL.0000000000011630&gt;10.1212&#x2F;WNL.0000000000011630&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33608417&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":30,"discovery_date":"2018-11-01","title":"Sexual dimorphism in immunometabolism and autoimmunity: Impact on personalized medicine","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Autoimmun Rev. 2021 Feb 17:102775. doi: 10.1016&#x2F;j.autrev.2021.102775. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Immune cells play essential roles in metabolic homeostasis and thus, undergo analogous changes in normal physiology (e.g., puberty and pregnancy) and in various metabolic and immune diseases. An essential component of this close relationship between the two is sex differences. Many autoimmune diseases, such as systemic lupus erythematous and multiple sclerosis, feature strikingly increased prevalence in females, whereas in contrast, infectious diseases, such as Ebola and Middle East Respiratory Syndrome, affect more men than women. Therefore, there are fundamental aspects of metabolic homeostasis and immune functions that are regulated differently in males and females. This can be observed in sex hormone-immune interaction where androgens, such as testosterone, have shown immunosuppressive effects whilst estrogen is on the opposite side of the spectrum with immunoenhancing facilitation of mechanisms. In addition, the two sexes exhibit significant differences in metabolic regulation, with estrous cycles in females known to induce variability in traits and more pronounced metabolic disease phenotype exhibited by males. It is likely that these differences underlie both the development of metabolic and autoimmune diseases and the response to current treatment options. Sexual dimorphism in immunometabolism has emerged to become an area of intense research, aiming to uncover sex-biased effector molecules in the various metabolic tissues and immune cell types, identify sex-biased cell-type-specific functions of common effector molecules, and understand whether the sex differences in metabolic and immune functions influence each other during autoimmune pathogenesis. In this review, we will summarize recent findings that address these critical questions of sexual dimorphism in immunometabolism as well as their translational implications for the clinical management of autoimmune diseases.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609790&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2&quot;&gt;33609790&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.autrev.2021.102775&gt;10.1016&#x2F;j.autrev.2021.102775&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609790&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":29,"discovery_date":"2018-11-01","title":"Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neurol. 2021 Feb 20. doi: 10.1007&#x2F;s00415-021-10466-0. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;NO ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609155&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2&quot;&gt;33609155&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s00415-021-10466-0&gt;10.1007&#x2F;s00415-021-10466-0&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609155&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":28,"discovery_date":"2018-11-01","title":"Menopause does not modify disability trajectories in a longitudinal cohort of women with CIS and MS followed from disease onset","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Eur J Neurol. 2021 Feb 20. doi: 10.1111&#x2F;ene.14782. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: to evaluate the effect of menopause on disability accumulation in women followed from their clinically isolated syndrome (CIS).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: We examined the longitudinal changes in EDSS from CIS until the last follow-up in women belonging to the Barcelona CIS prospective cohort, followed through their menopausal transition. The analysis is based on 13,718 EDSS measurements with an average of 28 EDSS per patient. Differences in EDSS trajectories between menopausal and non-menopausal women, controlling for age and disease duration were evaluated. We performed two sensitivity analyses, in women with confirmed MS and in those experiencing and early menopause.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: from 764 eligible women, 496 (65%) responded to the questionnaire and 74 (14.9%) reached menopause over follow-up. We did not find a significant inflection point in EDSS trajectories around menopause (slope change -0.009 (95%CI -0.066; 0.046). The annual increase in EDSS over the complete course of the disease was significantly higher in menopausal women (0.049 IC 95% 0.026 - 0.074) versus non-menopausal (0.019 IC 95% 0.008 - 0.031, interaction p-value 0.025). This difference was lost once controlling for age and disease duration (EDSS annual increase of 0.059 95% CI 0.025- 0.094 vs 0.038 IC 95% 0.021 - 0.057 respectively, interaction p-value 0.321). No inflection point was detected when the analysis was restricted to women with confirmed MS or with earlier menopause.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: menopause is not associated with an increased risk of disability in a CIS population, considering EDSS trajectories throughout the course of the disease, together with age and disease duration.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609298&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2&quot;&gt;33609298&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1111&#x2F;ene.14782&gt;10.1111&#x2F;ene.14782&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609298&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":27,"discovery_date":"2018-11-01","title":"Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Eur J Hosp Pharm. 2021 Mar;28(2):112-114. doi: 10.1136&#x2F;ejhpharm-2019-002048. Epub 2019 Oct 16.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To estimate the risk of progressive multifocal leukoencephalopathy (PML) and the safety of natalizumab administration in patients with relapsing-remitting multiple sclerosis (RRMS).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: A descriptive retrospective observational study including all patients with RRMS treated with natalizumab followed-up after 10 years.The likelihood of developing PML was estimated based on three risk factors: anti-John Cunningham virus antibody index, previous immunosuppressive therapy, and duration of treatment. Patients were classified into five categories: minimum probability (&amp;lt;0.1&#x2F;1000); low (0.1&#x2F;1000); medium-low (0.2-0.6&#x2F;1000); medium-high (0.8-3&#x2F;1000); high probability (3-10&#x2F;1000).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: 34 patients were included. The probability of PML in the last cycle was: 55.9% minimum, 8.8% low, 11.8% medium-low, 3% medium-high, and 20.5% high. 12 patients continue with active treatment with natalizumab. No cases of PML have been confirmed. Adverse effects were detected in 50% of patients.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Quantifying risk factors allows us to estimate the probability of PML appearance, thus assessing the maintenance or suspension of natalizumab.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33608441&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2&quot;&gt;33608441&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1136&#x2F;ejhpharm-2019-002048&gt;10.1136&#x2F;ejhpharm-2019-002048&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33608441&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":26,"discovery_date":"2018-11-01","title":"Microglial phagocytosis of neurons in neurodegeneration, and its regulation","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neurochem. 2021 Feb 20. doi: 10.1111&#x2F;jnc.15327. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;There is growing evidence that excessive microglial phagocytosis of neurons and synapses contributes to multiple brain pathologies. RNA-seq and genome wide association (GWAS) studies have linked multiple phagocytic genes to neurodegenerative diseases, and knock-out of phagocytic genes has been found to protect against neurodegeneration in animal models, suggesting that excessive microglial phagocytosis contributes to neurodegeneration. Here, we review recent evidence that microglial phagocytosis of live neurons and synapses causes neurodegeneration in animal models of Alzheimer&#39;s disease and other tauopathies, Parkinson&#39;s disease, frontotemporal dementias, multiple sclerosis, retinal degeneration, and neurodegeneration induced by ischaemia, infection or ageing. We also review factors regulating microglial phagocytosis of neurons, including: nucleotides, frackalkine, phosphatidylserine, calreticulin, UDP, CD47, sialylation, complement, galectin-3, Apolipoprotein E, phagocytic receptors, Siglec receptors, cytokines, microglial epigenetics and expression profile. Some of these factors may be potential treatment targets to prevent neurodegeneration mediated by excessive microglial phagocytosis of live neurons and synapses.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33608912&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2&quot;&gt;33608912&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1111&#x2F;jnc.15327&gt;10.1111&#x2F;jnc.15327&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33608912&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":25,"discovery_date":"2018-11-01","title":"B lymphocytes, the gastrointestinal tract and autoimmunity","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Autoimmun Rev. 2021 Feb 17:102777. doi: 10.1016&#x2F;j.autrev.2021.102777. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Under homeostatic conditions, bidirectional interactions between the gastrointestinal and the immune system allow production of both inflammatory and anti-inflammatory responses designed to prevent undesirable inflammation and to respond efficiently to potential insults. This balanced regulation can be disrupted in disorders that affect tissues remote to the gastrointestinal tract, as seen in autoimmune diseases. Recent reports have described a variety of B lymphocyte-mediated functions that likely contribute to gastrointestinal homeostasis to a greater extent than previously thought. Studies have shown that early B cell development takes place within the intestine, and that self-reactive B cells are rendered tolerant using mechanisms known to occur in the bone marrow, indicating that the gastrointestinal tract contributes to maintaining immune tolerance to self. Relatedly, continuous bacterial stimulation is essential for maintaining regulatory B cell functions and for mediating mucosal homeostasis. In studies of neuro-inflammation, intestinal IgA+ B cells, which constitute a prominent source of lymphocytes in the organism, can migrate to inflamed tissues and exert regulatory functions that attenuate inflammation in the central nervous system, indicating that, in addition to its local effects in the intestin, gut microbiota-B cell crosstalk can exert long-range beneficial effects. At the translational level, metabolites produced by gut microbiota can act as B cell-intrinsic epigenetic modulators, reducing inflammation in the skin and kidneys of mice suffering from experimental lupus. Given the significant impact of B cell-intestinal microbiota interactions, there is a momentum for improving our understanding of these pathways in autoinflammatory diseases and for designing novel therapeutic strategies for systemic autoimmune diseases where B cells play key roles.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609796&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2&quot;&gt;33609796&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.autrev.2021.102777&gt;10.1016&#x2F;j.autrev.2021.102777&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609796&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":24,"discovery_date":"2018-11-01","title":"Prevalence of neuromyelitis optica spectrum disorder in Belo Horizonte, Southeast Brazil","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 3;50:102807. doi: 10.1016&#x2F;j.msard.2021.102807. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Studies on the prevalence of neuromyelitis optica spectrum disorder (NMOSD) are still scarce. The aim of the current study was to determine the prevalence rate of NMOSD in Belo Horizonte, southeast Brazil, where the prevalence rate of multiple sclerosis (MS) has already been established.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: For this observational study, eligible patients had to meet the 2015 International Panel for Neuromyelitis Optica Diagnosis, be seen at the study center between January 2000 and February 2019 and live in Belo Horizonte. The prevalence rate of NMOSD was estimated based on the number of MS and NMOSD patients seen at same Center during the same period, and the previously established prevalence of MS in Belo Horizonte.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: During the study period, there were 69 patients with NMOSD, 60 (87.0%) of whom were females, and 44 (63.8%) non-whites. The median age at disease onset was 36.7 (4-72) years, the mean EDSS score 4.78±2.36, and the mean ARR 0.57±0.43. Anti-aquaporin-4 immunoglobulin testing was available for 61 (88.4%) patients, of whom 41 (67.2%) had a positive result. During the same period, 280 MS patients were seen. Considering the local known prevalence rate of MS of 18.1&#x2F;100,000 inhabitants, the estimated NMOSD prevalence rate in Belo Horizonte was 4.52&#x2F;100,000 (95% CI 3.72-5.43) inhabitants.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: The prevalence rate of NMOSD in Belo Horizonte is high as compared with those found in most of the studies reported to date.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609926&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2&quot;&gt;33609926&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102807&gt;10.1016&#x2F;j.msard.2021.102807&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609926&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":23,"discovery_date":"2018-11-01","title":"Association between familial Mediterranean fever and multiple sclerosis: A case series from the JIR cohort and systematic literature review","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 10;50:102834. doi: 10.1016&#x2F;j.msard.2021.102834. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTRODUCTION: Familial Mediterranean fever (FMF) is the most frequent monogenic autoinflammatory disorder; and leads to the uncontrolled production of interleukin (IL)-1β. Multiple sclerosis (MS) is an inflammatory disease of the central nervous system; and its development seems to be partly correlated with IL-1β levels. It is hypothesized that FMF could be associated with MS. We aim to describe the features of patients displaying both diseases and to investigate the MEFV mutation rate in MS patients.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Patients with definite MS were retrieved from the cohort of FMF patients in the Reference Center for Rare Auto-inflammatory Diseases and Amyloidosis (CEREMAIA). We also performed a systematic literature review of articles from PubMed that were published from 1990 to 2020.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Twenty-four patients were included in the case series: five patients (1.3%) from our cohort of 364 and 19 patients from the literature. The sex ratio was 2:1. The mean age at diagnosis of FMF was 19 years old; and that for MS was 29 years old. Seven studies investigating the MEFV mutation rate in MS patients were included. Three studies found a higher mutation rate in MS patients than in the control group.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: FMF and MS features were comparable to those of patients with unrelated diseases; and MEFV mutation carriage was not positively correlated with MS. However; MS prevalence in FMF patients was higher than was expected in a healthy population. To a lesser extent; FMF prevalence in MS patients was higher than expected in a healthy population and the difference might not be significant. These data suggest that FMF could be associated with MS; and further studies are needed to investigate a potential causal association.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609923&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2&quot;&gt;33609923&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102834&gt;10.1016&#x2F;j.msard.2021.102834&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609923&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":22,"discovery_date":"2018-11-01","title":"Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Jan 13;49:102754. doi: 10.1016&#x2F;j.msard.2021.102754. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Coronavirus disease 2019 (COVID-19) raises particular concerns for people with multiple sclerosis (PwMS) on disease-modifying treatments (DMTs), and for physicians caring for them. The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on PwMS receiving DMTs that inhibit immune cell trafficking, such as natalizumab (NTZ) and fingolimod (FTY), remains to be determined, as do the possible effects of these drugs on both the infection and the related disease.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;AIMS: To describe self-reported COVID-19 symptoms and disease severity in PwMS on NTZ or FTY who received serology confirmation of SARS-CoV-2 infection.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: From 27th April to 3rd May 2020, telephone interviews were conducted with 140 PwMS under treatment with NTZ or FTY in order to collect structured data on multiple sclerosis (MS) and COVID-19. The patients, all followed at our center, were classified as symptomatic, paucisymptomatic or asymptomatic on the basis of their self-reported clinical characteristics. COVID-19 severity was rated on a 7-point ordinal scale. In addition, in the period 4th May to 3rd June 2020 SARS-CoV-2 serology testing, using the Roche SARS-CoV-2 IgG assay (Elecsys&lt;sup&gt;Ⓡ&lt;&#x2F;sup&gt;), was performed in 104&#x2F;140 (74.2%) of the interviewed PwMS (50 treated with NTZ and 54 with FTY).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: 14&#x2F;104 (13.4%) PwMS on NTZ or FTY had anti-SARS-CoV-2 antibodies: 8 met the criteria for asymptomatic, 3 for paucisymptomatic and 3 for symptomatic COVID-19 (COVID-19 severity score lower than 3). None of them required hospitalization or showed severe COVID-19 complications.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Despite the relatively high SARS CoV-2 seroprevalence found in this sample of PwMS, all the positive cases showed either no or only mild COVID-19 symptoms. These reassuring findings indicate a lack of COVID-19 complications in PwMS on DMTs and support the hypothesis that it is safe to maintain ongoing treatment with these drugs in the current setting.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609958&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2&quot;&gt;33609958&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102754&gt;10.1016&#x2F;j.msard.2021.102754&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609958&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":21,"discovery_date":"2018-11-01","title":"Generation of six induced pluripotent stem cell lines from patients with amyotrophic lateral sclerosis with associated genetic mutations in either FUS or ANXA11","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Stem Cell Res. 2021 Feb 12;52:102246. doi: 10.1016&#x2F;j.scr.2021.102246. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Amyotrophic lateral sclerosis (ALS) is characterized by degeneration of upper and lower motor neurons, causing gradual paralysis, and resulting in death 3-5 years from diagnosis. ALS causative mutations have been identified in multiple genes, including Fused in sarcoma (FUS), and recently characterized Annexin A11 (ANXA11). We have derived induced pluripotent stem cell (iPSC) lines from six ALS patient lymphoblastoid cell lines, three with mutations in FUS (Q519E, R521H, R522G), and three with mutations in ANXA11 (G38R, D40G, R235Q). These lines have been characterized and provide a novel resource for investigation into ALS pathology.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33610019&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2&quot;&gt;33610019&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.scr.2021.102246&gt;10.1016&#x2F;j.scr.2021.102246&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33610019&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":20,"discovery_date":"2018-11-01","title":"Varicella zoster-associated acute retinal necrosis and central nervous system complications in natalizumab treated MS patients","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Feb 10;50:102838. doi: 10.1016&#x2F;j.msard.2021.102838. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;There is not much awareness of varicella zoster virus (VZV) associated central nervous system (CNS) infections under treatment with natalizumab. Here we describe two natalizumab treated MS patients who developed acute retinal necrosis combined with CNS vasculitis caused by VZV. In natalizumab treated patients, visual symptoms atypical of optic neuritis should be promptly evaluated by an ophthalmologist. Currently, a total of 12 cases of natalizumab-associated VZV CNS or retinal infections are reported in literature. Our two cases and overview of currently available data provide information on prognosis and treatment decisions of this rare but devastating complication.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609925&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2&quot;&gt;33609925&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102838&gt;10.1016&#x2F;j.msard.2021.102838&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609925&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":19,"discovery_date":"2018-11-01","title":"Disability measurement in Multiple Sclerosis patients 55 years and older: What is the Expanded Disability Status Scale really telling clinicians?","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2020 Dec 28;49:102724. doi: 10.1016&#x2F;j.msard.2020.102724. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: The Expanded Disability Status Scale (EDSS) measures disease progression in Multiple Sclerosis (MS). EDSS changes are assumed to be due to worsening MS-related disability. Strict interpretation of this premise may include some normal findings as abnormal, inflating the disability score. Further, determining the cause of neurologic symptoms can be difficult in an older population with comorbid illness and polypharmacy.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To examine the association between EDSS, age, comorbidities and polypharmacy.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: 106 people, 55 years and older, with and without MS were administered the EDSS and a validated comorbidity questionnaire. Polypharmacy was also assessed.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Median EDSS scores were 6.0 in people with MS and 3.0 in people without MS. No participant in our cohort had an EDSS of 0. Higher EDSS scores were associated with older age and more polypharmacy. Pyramidal and cerebellar functional systems accounted for the largest percentage of unique variance between groups.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Older individuals with and without MS demonstrated significant disability on the EDSS. These findings indicate that EDSS scores may be partially due to factors other than MS. Our understanding of disease course and disability may benefit from the development of normative EDSS scores to correct for these factors.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609959&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2&quot;&gt;33609959&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2020.102724&gt;10.1016&#x2F;j.msard.2020.102724&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609959&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":18,"discovery_date":"2018-11-01","title":"Perilesional neurodegenerative injury in multiple sclerosis: Relation to focal lesions and impact on disability","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler Relat Disord. 2021 Jan 5;49:102738. doi: 10.1016&#x2F;j.msard.2021.102738. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Axonal injury is the primary source of irreversible neurological decline in persons with multiple sclerosis (pwMS). Identifying and quantifying myelin and axonal loss in lesional and perilesional tissue in vivo is fundamental for a better understanding of multiple sclerosis (MS) outcomes and patient impairment. Using advanced magnetic resonance imaging (MRI) methods, consisting of selective inversion recovery quantitative magnetization transfer imaging (SIR-qMT) and multi-compartment diffusion MRI with the spherical mean technique (SMT), we conducted a cross-sectional pilot study to assess myelin and axonal damage in the normal appearing white matter (NAWM) surrounding chronic black holes (cBHs) and how this pathology correlates with disability in vivo. We hypothesized that lesional axonal transection propagates tissue injury in the surrounding NAWM and that the degree of this injury is related to patient disability.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: Eighteen pwMS underwent a 3.0 Tesla conventional clinical MRI, inclusive of T1 and T2 weighted protocols, as well as SIR-qMT and SMT. Regions of interests (ROIs) were manually delineated in cBHs, NAWM neighboring cBHs (perilesional NAWM), distant ipsilateral NAWM and contra-lateral distant NAWM. SIR-qMT-derived macromolecular-to-free pool size ratio (PSR) and SMT-derived apparent axonal volume fraction (V&lt;sub&gt;ax&lt;&#x2F;sub&gt;) were extracted to infer on myelin and axonal content, respectively. Group differences were assessed using mixed-effects regression models and correlation analyses were obtained by bootstrapping 95% confidence interval.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: In comparison to perilesional NAWM, both PSR and V&lt;sub&gt;ax&lt;&#x2F;sub&gt; values were reduced in cBHs (p &amp;lt; 0.0001) and increased in distant contra-lateral NAWM ROIs (p &amp;lt; 0.001 for PSR and p &amp;lt; 0.0001 for V&lt;sub&gt;ax&lt;&#x2F;sub&gt;) but not ipsilateral NAWM (p &#x3D; 0.176 for PSR and p &#x3D; 0.549 for V&lt;sub&gt;ax&lt;&#x2F;sub&gt;). V&lt;sub&gt;ax&lt;&#x2F;sub&gt; values measured in cBHs correlated with those in perilesional NAWM (Pearson rho &#x3D; 0.63, p &amp;lt; 0.001). No statistically relevant associations were seen between PSR&#x2F;V&lt;sub&gt;ax&lt;&#x2F;sub&gt; values and clinical and&#x2F;or MRI metrics of the disease with the exception of cBH PSR values, which correlated with the Expanded Disability Status Scale (Pearson rho &#x3D; -0.63, p &#x3D; 0.03).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: Our results show that myelin and axonal content, detected by PSR and V&lt;sub&gt;ax&lt;&#x2F;sub&gt;, are reduced in perilesional NAWM, as a function of the degree of focal cBH axonal injury. This finding is indicative of an ongoing anterograde&#x2F;retrograde degeneration and suggests that treatment prevention of cBH development is a key factor for preserving NAWM integrity in surrounding tissue. It also suggests that measuring changes in perilesional areas over time may be a useful measure of outcome for proof-of-concept clinical trials on neuroprotection and repair. PSR and V&lt;sub&gt;ax&lt;&#x2F;sub&gt; largely failed to capture associations with clinical and MRI characteristics, likely as a result of the small sample size and cross-sectional design, however, longitudinal assessment of a larger cohort may unravel the impact of this pathology on disease progression.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609957&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2&quot;&gt;33609957&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.msard.2021.102738&gt;10.1016&#x2F;j.msard.2021.102738&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33609957&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":17,"discovery_date":"2018-11-01","title":"Disruption of brainstem monoaminergic fibre tracts in multiple sclerosis as a putative mechanism for cognitive fatigue: a fixel-based analysis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Neuroimage Clin. 2021 Feb 12;30:102587. doi: 10.1016&#x2F;j.nicl.2021.102587. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;In multiple sclerosis (MS), monoaminergic systems are altered as a result of both inflammation-dependent reduced synthesis and direct structural damage. Aberrant monoaminergic neurotransmission is increasingly considered a major contributor to fatigue pathophysiology. In this study, we aimed to compare the integrity of the monoaminergic white matter fibre tracts projecting from brainstem nuclei in a group of patients with MS (n &#x3D; 68) and healthy controls (n &#x3D; 34), and to investigate its association with fatigue. Fibre tracts integrity was assessed with the novel fixel-based analysis that simultaneously estimates axonal density, by means of &#39;fibre density&#39;, and white matter atrophy, by means of fibre &#39;cross section&#39;. We focused on ventral tegmental area, locus coeruleus, and raphe nuclei as the main source of dopaminergic, noradrenergic, and serotoninergic fibres within the brainstem, respectively. Fourteen tracts of interest projecting from these brainstem nuclei were reconstructed using diffusion tractography, and compared by means of the product of fibre-density and cross-section (FDC). Finally, correlations of monoaminergic axonal damage with the modified fatigue impact scale scores were evaluated in MS. Fixel-based analysis revealed significant axonal damage - as measured by FDC reduction - within selective monoaminergic fibre-tracts projecting from brainstem nuclei in MS patients, in comparison to healthy controls; particularly within the dopaminergic-mesolimbic pathway, the noradrenergic-projections to prefrontal cortex, and serotoninergic-projections to cerebellum. Moreover, we observed significant correlations between severity of cognitive fatigue and axonal damage within the mesocorticolimbic tracts projecting from ventral tegmental area, as well as within the locus coeruleus projections to prefrontal cortex, suggesting a potential contribution of dopaminergic and noradrenergic pathways to central fatigue in MS. Our findings support the hypothesis that axonal damage along monoaminergic pathways contributes to the reduction&#x2F;dysfunction of monoamines in MS and add new information on the mechanisms by which monoaminergic systems contribute to MS pathogenesis and fatigue. This supports the need for further research into monoamines as therapeutic targets aiming to combat and alleviate fatigue in MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33610097&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2&quot;&gt;33610097&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.nicl.2021.102587&gt;10.1016&#x2F;j.nicl.2021.102587&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33610097&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210221121510&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":16,"discovery_date":"2021-02-20T00:00:00.000Z","title":"ACT-1004-1239, a first-in-class CXCR7 antagonist with both immunomodulatory and promyelinating effects for the treatment of inflammatory demyelinating diseases - PubMed","summary":"Current strategies for the treatment of demyelinating diseases such as multiple sclerosis (MS) are based on anti-inflammatory or immunomodulatory drugs. Those drugs have the potential to reduce the frequency of new lesions but do not directly promote remyelination in the damaged central nervous system (CNS). Targeting CXCR7 (ACKR3) has been postulated as a potential therapeutic approach in demyelinating diseases, leading to both immunomodulation by reducing leukocyte infiltrates and promyelination by enhancing myelin repair. ACT-1004-1239 is a potent, selective, insurmountable, and orally available first-in-class CXCR7 receptor antagonist. The effect of ACT-1004-1239 was evaluated in the myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE) and the cuprizone-induced demyelination mouse models. In addition, ACT-1004-1239 was assessed in a rat oligodendrocyte precursor cell (OPC) differentiation assay in vitro. In the MOG-induced EAE model, ACT-1004-1239 treatment (10-100 mg&#x2F;kg, twice daily, orally) showed a significant dose-dependent reduction in disease clinical scores, resulting in increased survival. At the highest dose tested (100 mg&#x2F;kg, twice daily), ACT-1004-1239 delayed disease onset and significantly reduced immune cell infiltrates into the CNS and plasma neurofilament light chain concentration. Treatment with ACT-1004-1239 dose-dependently increased plasma CXCL12 concentration, which correlated with a reduction of the cumulative disease score. Furthermore, in the cuprizone model, ACT-1004-1239 treatment significantly increased the number of mature myelinating oligodendrocytes and enhanced myelination in vivo. In vitro, ACT-1004-1239 promoted the maturation of OPCs into myelinating oligodendrocytes. These results provide evidence that ACT-1004-1239 both reduces neuroinflammation and enhances myelin repair substantiating the rationale to explore its therapeutic potential in a clinical setting.","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33595155&#x2F;","published_date":"2021-02-20T00:00:00.000Z","source":"FASEB","relevant":1,"table_constraints":null},{"article_id":15,"discovery_date":"2018-11-01","title":"First measured retinal nerve fiber layer thickness in RRMS can be used as a biomarker for the course of the disease: threshold value discussions","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neurol. 2021 Feb 19. doi: 10.1007&#x2F;s00415-021-10469-x. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Peripapillary retinal nerve fiber layer thickness correlates with radiological and clinical parameters in patients with MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: The aim of this study is to investigate the use of the first measured pRNFL thickness as a predictor of disease course in patients with RRMS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: One hundred and thirty seven RRMS patients were enrolled in the study within the first 5 years of illness. Patients were followed for 34.1 months and the EDSS was used to assess disability status to determine whether the first measured pRNFL thickness, using proportional hazards models, predicts the risk of disability worsening.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: The mean disease duration was 26.1 months. Disability worsening was detected in 36 patients. In tertile-based groups formed according to pRNFL thickness, the group with the lowest pRNFL thickness had a 2.8-fold increase in the risk of disability worsening compared to the group with the highest. The risk was higher in the first 2 years of the study (HR &#x3D; 3.48; p &#x3D; 0.008).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: The first measured pRNFL thickness in RRMS patients can predict the risk of disability worsening, and the risk of disability worsening in the early period was higher in the group with the lowest pRNFL value.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33606071&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;33606071&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s00415-021-10469-x&gt;10.1007&#x2F;s00415-021-10469-x&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33606071&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":14,"discovery_date":"2018-11-01","title":"Healthcare access experiences of persons with MS explored through the Candidacy Framework","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Health Soc Care Community. 2021 Feb 19. doi: 10.1111&#x2F;hsc.13320. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Canada has one of the highest rates of multiple sclerosis (MS) in the world, affecting 1 in every 385 individuals. This neurodegenerative condition is unpredictable and variable in symptom profile and disease course making it difficult to manage. Canadians with MS are high users of healthcare services; however, they report multiple unmet needs, high disease burden, and low satisfaction with healthcare. Access to healthcare is vital to health maintenance and may explain these poor experiences. Access is often measured using utilisation as a proxy, which may fail to capture the complexities of access experiences that this population faces. The Candidacy Framework offers an alternative to utilisation measures, by examining the process of accessing care, while considering the impact of social patterning and health system environments on this process. The aim of the current study is to align the experiences of persons with MS in accessing healthcare services with the stages of the Candidacy Framework. Forty-eight individuals with MS living across Ontario were recruited to participate in one of five focus groups or ten individual interviews. Analysis included a first inductive phase, using constant comparative methods, followed by a deductive phase, using content analysis. The Candidacy Framework was not able to capture all experiences shared by persons with MS, including patient-centred care, past experiences and outcome expectation, and care outcomes. We propose these concepts be included as refinements to the current Framework, providing a more thorough explanation of the experiences of persons with MS in accessing care to manage their condition.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33606904&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;33606904&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1111&#x2F;hsc.13320&gt;10.1111&#x2F;hsc.13320&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33606904&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":13,"discovery_date":"2018-11-01","title":"Hidradenitis suppurativa - The role of interleukin-17, the aryl hydrocarbon receptor and the link to a possible fungal aetiology","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Med Hypotheses. 2021 Feb 10;149:110530. doi: 10.1016&#x2F;j.mehy.2021.110530. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Hidradenitis Suppurativa (HS) is a chronic, recurrent, debilitating skin disease of the hair follicle that usually presents after puberty with painful, deep-seated, inflamed lesions in the apocrine gland bearing areas of the body, most commonly the axillae, inguinal and anogenital regions. The pathophysiology of the disease remains elusive, with newer therapies targeting various aspects of the dysregulated immune system. This presents a useful opportunity to look at the cytokine profile in HS and other inflammatory conditions that share similar patterns with the aim of teasing out less considered explanations for HS pathogenesis. It has been observed that IL-17 appears to be the most common denominator linking HS with other immune mediated diseases like Crohn, ulcerative colitis, multiple sclerosis and psoriasis. Given that IL-17 plays an important role in antifungal immunity, evidenced by the cytokine pattern in fungal disease and the bulk of data citing their potential involvement in Crohn, ulcerative colitis, multiple sclerosis and psoriasis; it is fair to suggest the need to explore the role that fungi play in the setting of HS going forward. The aryl hydrocarbon receptor (ahr) is a ubiquitous and largely conserved entity that is gaining interest in inflammatory conditions such as psoriasis and atopic dermatitis. It is well known to modulate autoimmune states. Its activation by both exogenous and endogenous agents result in secretion of IL-17 by Th17 cells. One of such agents is the tryptophan metabolite 6-formylindolo [3,2-b] carbazole (FICZ)-which can be produced by microorganisms such as fungi. It will be interesting to explore its usefulness in HS pathogenesis.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33607406&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;33607406&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.mehy.2021.110530&gt;10.1016&#x2F;j.mehy.2021.110530&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33607406&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":12,"discovery_date":"2018-11-01","title":"Depression and multiple sclerosis: A bidirectional Mendelian randomisation study","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Feb 19:1352458521996601. doi: 10.1177&#x2F;1352458521996601. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Depression is common in multiple sclerosis (MS); however, the underlying mechanism for the relationship remains unknown. In this study, we examined a putative causal relationship between depression and MS using a bidirectional Mendelian randomisation (MR) framework. Using the latest genome-wide association study data available, 168 non-major histocompatibility complex (MHC) independent variants associated with MS and 96 independent genetic variants associated with depression susceptibility were used. Maximum likelihood, weighted median, inverse variance weighted method and MR-Egger regression analyses were performed. There was no significant risk for the development of MS in persons carrying variants associated with depression or for risk of depression in individuals who are genetically susceptible to MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33605804&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;33605804&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;1352458521996601&gt;10.1177&#x2F;1352458521996601&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33605804&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":11,"discovery_date":"2018-11-01","title":"The relative contributions of obesity, vitamin D, leptin, and adiponectin to multiple sclerosis risk: A Mendelian randomization mediation analysis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Mult Scler. 2021 Feb 19:1352458521995484. doi: 10.1177&#x2F;1352458521995484. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Obesity is associated with increased risk of multiple sclerosis (MS); however, the underlying mechanisms remain unclear.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;OBJECTIVE: To determine the extent to which decreased vitamin D bioavailability and altered levels of adiponectin and leptin mediate the association between obesity and MS.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: We performed Mendelian randomization (MR) analyses to estimate the effects on MS of body mass index (BMI), 25-hydroxyvitamin D (25OHD), adiponectin, and leptin levels in a cohort of 14,802 MS cases and 26,703 controls. We then estimated the proportion of the effect of obesity on MS explained by these potential mediators.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: Genetic predisposition to higher BMI was associated with increased MS risk (odds ratio (OR) &#x3D; 1.33 per standard deviation (SD), 95% confidence interval (CI) &#x3D; 1.09-1.63), while higher 25OHD levels reduced odds of MS (OR &#x3D; 0.72 per SD, 95% CI &#x3D; 0.60-0.87). In contrast, we observed no effect of adiponectin or leptin. In MR mediation analysis, 5.2% of the association between BMI and MS was attributed to obesity lowering 25OHD levels (95% CI &#x3D; 0.3%-31.0%).&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSIONS: This study found that a minority of the increased risk of MS conferred by obesity is mediated by lowered vitamin D levels, while leptin and adiponectin had no effect. Consequently, vitamin D supplementation would only modestly reverse the effect of obesity on MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33605807&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;33605807&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1177&#x2F;1352458521995484&gt;10.1177&#x2F;1352458521995484&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33605807&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":10,"discovery_date":"2018-11-01","title":"N-Acetyl-Lysyltyrosylcysteine Amide, a Novel Systems Pharmacology Agent, Reduces Bronchopulmonary Dysplasia in Hyperoxic Neonatal Rat Pups","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Free Radic Biol Med. 2021 Feb 16:S0891-5849(21)00079-4. doi: 10.1016&#x2F;j.freeradbiomed.2021.02.006. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Bronchopulmonary dysplasia (BPD) is caused primarily by oxidative stress and inflammation. To induce BPD, neonatal rat pups were raised in hyperoxic (&amp;gt;90% O&lt;sub&gt;2&lt;&#x2F;sub&gt;) environments from day one (P1) until day ten (P10) and treated with N-acetyl-lysyltyrosylcysteine amide (KYC). In vivo studies showed that KYC improved lung complexity, reduced myeloperoxidase (MPO) positive (+) myeloid cell counts, MPO protein, chlorotyrosine formation, increased endothelial cell CD31 expression, decreased 8-OH-dG and Cox-1&#x2F;Cox-2, HMGB1, RAGE, TLR4, increased weight gain and improved survival in hyperoxic pups. EPR studies confirmed that MPO reaction mixtures oxidized KYC to a KYC thiyl radical. Adding recombinant HMGB1 to the MPO reaction mixture containing KYC resulted in KYC thiylation of HMGB1. In rat lung microvascular endothelial cell (RLMVEC) cultures, KYC thiylation of RLMVEC proteins was increased the most in RLMVEC cultures treated with MPO+H&lt;sub&gt;2&lt;&#x2F;sub&gt;O&lt;sub&gt;2&lt;&#x2F;sub&gt;, followed by H&lt;sub&gt;2&lt;&#x2F;sub&gt;O&lt;sub&gt;2&lt;&#x2F;sub&gt;, and then KYC alone. KYC treatment of hyperoxic pups decreased total HMGB1 in lung lysates, increased KYC thiylation of HMGB1, terminal HMGB1 thiol oxidation, decreased HMGB1 association with TLR4 and RAGE, and shifted HMGB1 in lung lysates from a non-acetylated to a lysyl-acetylated isoform, suggesting that KYC reduced lung cell death and that recruited immune cells had become the primary source of HMGB1 released into the hyperoxic lungs. MPO-dependent and independent KYC-thiylation of Keap1 were both increased in RLMVEC cultures. Treating hyperoxic pups with KYC increased KYC thiylation and S-glutathionylation of Keap1, and Nrf2 activation. These data suggest that KYC is a novel system pharmacological agent that exploits MPO to inhibit toxic oxidant production and is oxidized into a thiyl radical that inactivates HMGB1, activates Nrf2, and increases antioxidant enzyme expression to improve lung complexity and reduce BPD in hyperoxic rat pups.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33607217&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;33607217&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.freeradbiomed.2021.02.006&gt;10.1016&#x2F;j.freeradbiomed.2021.02.006&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33607217&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":9,"discovery_date":"2018-11-01","title":"CSF proteome in multiple sclerosis subtypes related to brain lesion transcriptomes","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Sci Rep. 2021 Feb 18;11(1):4132. doi: 10.1038&#x2F;s41598-021-83591-5.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;To identify markers in the CSF of multiple sclerosis (MS) subtypes, we used a two-step proteomic approach: (i) Discovery proteomics compared 169 pooled CSF from MS subtypes and inflammatory&#x2F;degenerative CNS diseases (NMO spectrum and Alzheimer disease) and healthy controls. (ii) Next, 299 proteins selected by comprehensive statistics were quantified in 170 individual CSF samples. (iii) Genes of the identified proteins were also screened among transcripts in 73 MS brain lesions compared to 25 control brains. F-test based feature selection resulted in 8 proteins differentiating the MS subtypes, and secondary progressive (SP)MS was the most different also from controls. Genes of 7 out these 8 proteins were present in MS brain lesions: GOLM was significantly differentially expressed in active, chronic active, inactive and remyelinating lesions, FRZB in active and chronic active lesions, and SELENBP1 in inactive lesions. Volcano maps of normalized proteins in the different disease groups also indicated the highest amount of altered proteins in SPMS. Apolipoprotein C-I, apolipoprotein A-II, augurin, receptor-type tyrosine-protein phosphatase gamma, and trypsin-1 were upregulated in the CSF of MS subtypes compared to controls. This CSF profile and associated brain lesion spectrum highlight non-inflammatory mechanisms in differentiating CNS diseases and MS subtypes and the uniqueness of SPMS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33603109&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;33603109&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1038&#x2F;s41598-021-83591-5&gt;10.1038&#x2F;s41598-021-83591-5&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33603109&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":8,"discovery_date":"2018-11-01","title":"Oxidized phosphatidylcholines found in multiple sclerosis lesions mediate neurodegeneration and are neutralized by microglia","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Nat Neurosci. 2021 Feb 18. doi: 10.1038&#x2F;s41593-021-00801-z. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;Neurodegeneration occurring in multiple sclerosis (MS) contributes to the progression of disability. It is therefore important to identify and neutralize the mechanisms that promote neurodegeneration in MS. Here, we report that oxidized phosphatidylcholines (OxPCs) found in MS lesions, previously identified as end-product markers of oxidative stress, are potent drivers of neurodegeneration. Cultured neurons and oligodendrocytes were killed by OxPCs, and this was ameliorated by microglia. After OxPC injection, mouse spinal cords developed focal demyelinating lesions with prominent axonal loss. The depletion of microglia that accumulated in OxPC lesions exacerbated neurodegeneration. Single-cell RNA sequencing of lesioned spinal cords identified unique subsets of TREM2&lt;sup&gt;high&lt;&#x2F;sup&gt; mouse microglia responding to OxPC deposition. TREM2 was detected in human MS lesions, and TREM2&lt;sup&gt;-&#x2F;-&lt;&#x2F;sup&gt; mice exhibited worsened OxPC lesions. These results identify OxPCs as potent neurotoxins and suggest that enhancing microglia-mediated OxPC clearance via TREM2 could help prevent neurodegeneration in MS.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33603230&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;33603230&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1038&#x2F;s41593-021-00801-z&gt;10.1038&#x2F;s41593-021-00801-z&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33603230&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":7,"discovery_date":"2018-11-01","title":"Binocular Vision in Patients with Multiple Sclerosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Clin Optom (Auckl). 2021 Feb 12;13:39-49. doi: 10.2147&#x2F;OPTO.S286862. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;PURPOSE: Oculomotor disorders have been reported in multiple sclerosis (MS) in up to 80% of cases. There have been studies evaluating binocular vision in several neurological diseases, but not in MS. Considering that a high percentage of eye-movement anomalies have been reported, the aim of this study was to analyze binocular vision in these subjects.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;METHODS: A total of 59 participants with MS - 21 with monocular optic neuritis, eleven with binocular optic neuritis, and 27 without optic neuritis - and 26 age-matched controls were enrolled. Binocular vision was analyzed using near point of convergence (NPC), positive and negative fusional vergence for far and near distance, measurement of heterophoria at both distances with cover and modified Thorington tests, and random-dot stereoscopy.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;RESULTS: The percentage of subjects with abnormal NPC values was highest in the MS group, followed by the MSONm (MS with optic neuritis in one eye), MSONb (MS with optic neuritis in both eyes), and control groups. MS patients showed an esophoric trend at near distance. Positive fusional vergence showed no significant differences between control and MS groups, but higher variability in recovery was found in MS groups. Negative fusional vergence at near distance showed significant differences between the control group and the two MS groups, with optic neuritis for both break-point and recovery values. A high percentage of patients with MS had alterations on stereopsis.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Alterations in binocular vision were present in MS, with divergence at near distance and stereopsis the most affected parameters. Likewise, MS patients with optic neuritis showed worse binocular vision.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33603529&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;33603529&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7886387&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;PMC7886387&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.2147&#x2F;OPTO.S286862&gt;10.2147&#x2F;OPTO.S286862&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33603529&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":6,"discovery_date":"2018-11-01","title":"The Therapeutic Targets of Fingolimod (FTY720) Are Involved in Pathological Processes in the Frontal Cortex of Alzheimer&#39;s Disease Patients: A Network Pharmacology Study","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Front Aging Neurosci. 2021 Feb 2;13:609679. doi: 10.3389&#x2F;fnagi.2021.609679. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;&lt;b&gt;Background:&lt;&#x2F;b&gt; The sphingosine-1-phosphate receptor (S1PR) modulator fingolimod (FTY720), which is commonly used as an immunomodulator in multiple sclerosis treatment, has recently been found to reduce pathological changes in the brain tissue of Alzheimer&#39;s disease (AD) animal models, but this has yet to be verified in human brain tissue. In this study, network pharmacology methods were applied to determine the potential pharmacological mechanisms of fingolimod in the frontal cortex of AD patients. &lt;b&gt;Methods:&lt;&#x2F;b&gt; The pharmacological macromolecular targets of fingolimod and fingolimod phosphate were downloaded from SwissTarget and DrugBank. Systematic intersection analysis of the expression profiles of brain frontal cortex tissues (423 AD tissues and 266 control tissues) was performed to obtain AD-associated fingolimod targets (F-ADGs). Immune cell infiltration analysis and a primary mouse cortical culture RNA-seq drug screen database were used to identify immune-related F-ADGs and cortex-related F-ADGs. Then, the expression values of F-ADGs were correlated with the disease severity score (MMSE score) of AD patients to identify severity-related F-ADGs. We also analyzed miRNA expression microarray data in the frontal cortex of AD patients associated with disease severity to obtain severity-related F-ADG-miRNAs. &lt;b&gt;Results:&lt;&#x2F;b&gt; A total of 188 F-ADGs were detected in the frontal cortices of AD patients and were enriched in biological processes such as synaptic signaling, inflammatory response, and response to oxygen-containing compounds. Eleven immune-related F-ADGs (like FPR1, BLNK.) and 17 cortex-related F-ADGs (like ALDH1L1, DUSP1.) were detected. Other F-ADGs, such as S1PR1 and GABBR2, although not classified into the above two categories, were still predicted by bioinformatics methods to play an important role in the development of AD. Two F-ADGs (GNAQ and MMP14) and 28 miRNAs (like miR- 323a-3p, miR-181a-5p.) were found to be associated with AD severity (MMSE 0-27 group). Fifteen F-ADGs (like ALDH1L1, FPR1, and IL6.) and 46 miRNAs (like miR-212-5p, miR-93-5p.) were found to be associated with mild or moderate dementia AD patients&#39; severity (MMSE11-22 subgroup). &lt;b&gt;Conclusions:&lt;&#x2F;b&gt; Fingolimod may affect the brain frontal cortex function of AD patients in many different ways, such as affecting immune cell infiltration, nerve cell, or glial cell function, and synaptic function. miRNAs may also be involved. ALDH1L1, FPR1, S1PR1, and GABBR2 may be core drug targets.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33603656&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;33603656&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7884771&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;PMC7884771&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.3389&#x2F;fnagi.2021.609679&gt;10.3389&#x2F;fnagi.2021.609679&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33603656&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":5,"discovery_date":"2018-11-01","title":"Evaluation of Urinary Tract Infection following Corticosteroid Therapy in Patients with Multiple Sclerosis Exacerbation","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Can J Infect Dis Med Microbiol. 2021 Jan 31;2021:6616763. doi: 10.1155&#x2F;2021&#x2F;6616763. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;The first treatment for multiple sclerosis exacerbation is usually short-term intravenous methylprednisolone (IVMP), with or without a regimen of oral prednisone taper (OPT). This study aims to evaluate the effects of IVMP and OPT in comparison with IVMP alone in raising the risk of urinary tract infection (UTI) and posttreatment improvement of urinary tract symptoms in patients with relapsing-remitting multiple sclerosis. This double-blind randomized clinical trial was conducted on 56 people with multiple sclerosis relapse who had undergone methylprednisolone for 5 days. Patients were randomly split into two groups: oral prednisolone and placebo (tapering for 20 days). Demographic data, duration of multiple sclerosis, urinary tract symptoms, the Expanded Disability Status Scale (EDSS) score, and urine data were analyzed. The incidence of UTI in the intervention and control groups did not differ significantly (&lt;i&gt;p&lt;&#x2F;i&gt;&#x3D;560). However, the improvement of urinary tract symptoms in the intervention group was significantly more favorable than in the control group (&lt;i&gt;p&lt;&#x2F;i&gt; ≤ 0.001). Furthermore, administering OPT after IVMP did not increase the risk of UTI occurrence in patients with multiple sclerosis exacerbation. The urine analysis results did not show any differences at baseline and after the corticosteroid tapering regimen. Due to the risk of infection by corticosteroids, it is no longer necessary to do further urinary screening in this group of patients.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33603936&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;33603936&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7870309&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;PMC7870309&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1155&#x2F;2021&#x2F;6616763&gt;10.1155&#x2F;2021&#x2F;6616763&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33603936&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":4,"discovery_date":"2018-11-01","title":"Rare Case of Spinal Neurosarcoidosis with Concomitant Epidural Lipomatosis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Case Rep Neurol Med. 2021 Jan 28;2021:5952724. doi: 10.1155&#x2F;2021&#x2F;5952724. eCollection 2021.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;INTRODUCTION: Spinal neurosarcoidosis is a rare disease that can manifest as myelopathy, radiculopathy, or cauda equine syndrome. Spinal epidural lipomatosis is also a rare condition resulting from overgrowth of epidural fat tissue causing compressive myelopathy. To our knowledge, there are no reports linking epidural lipomatosis and spinal neurosarcoidosis. &lt;i&gt;Case Report&lt;&#x2F;i&gt;. We describe a case of progressive myelitis in the presence of concomitant spinal neurosarcoidosis and epidural lipomatosis which was a challenging diagnosis with complete response to treatment after addressing both diseases. Both etiologies are inflammatory in nature and share similar expression of inflammatory factors such as TNF-&lt;i&gt;α&lt;&#x2F;i&gt; and IL-1&lt;i&gt;β&lt;&#x2F;i&gt;.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: The common inflammatory process involved in these two diseases might explain a pathophysiological interconnection between both diseases that may underlie their concomitant development in our patient. If these two diseases are interconnected, in their pathophysiological mechanism remains a hypothesis that will need further investigation.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33604089&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;33604089&lt;&#x2F;a&gt; | PMC:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;PMC7869444&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;PMC7869444&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1155&#x2F;2021&#x2F;5952724&gt;10.1155&#x2F;2021&#x2F;5952724&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33604089&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":3,"discovery_date":"2018-11-01","title":"Patient Satisfaction With the Quality of Counseling Provided by Advanced Practice Nurses Specialized in Multiple Sclerosis: A Quantitative Analysis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neurosci Nurs. 2021 Feb 17. doi: 10.1097&#x2F;JNN.0000000000000578. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: The challenges in dealing with multiple sclerosis (MS) have increased considerably in recent years. In addition to neurologists, MS nurse specialists are key to the management of MS patients, but there is a lack of evidence regarding their quality of counseling. METHODS: The data collection took place between October 2018 and March 2019 in the outpatient clinic of a university hospital. The quality of counseling was assessed using the APN-BQ, an instrument that contains 19 items that can be assigned to 4 dimensions. Participants were asked to rate their satisfaction on a scale from 0 to 3. General satisfaction was assessed on a scale from 0 to 100. RESULTS: The participants (n &#x3D; 110) rated the quality of counseling and their general satisfaction high. The mean (SD) of the structure quality dimension was 2.64 (0.44), and satisfaction with length and frequency of consultations (2.53 [0.63]) scored better than outcome quality (1.99 [0.62]) and process quality (2.13 [0.60]). CONCLUSION: Overall, there was a high rate of satisfaction with the quality of counseling. In addition to the length and frequency of consultations, MS patients particularly appreciated the availability and expertise of MS nurse specialists.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33605649&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;33605649&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1097&#x2F;JNN.0000000000000578&gt;10.1097&#x2F;JNN.0000000000000578&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33605649&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":2,"discovery_date":"2018-11-01","title":"Is Migraine Associated to Brain Anatomical Alterations? New Data and Coordinate-Based Meta-analysis","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;Brain Topogr. 2021 Feb 19. doi: 10.1007&#x2F;s10548-021-00824-6. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;A growing number of studies investigate brain anatomy in migraine using voxel- (VBM) and surface-based morphometry (SBM), as well as diffusion tensor imaging (DTI). The purpose of this article is to identify consistent patterns of anatomical alterations associated with migraine. First, 19 migraineurs without aura and 19 healthy participants were included in a brain imaging study. T1-weighted MRIs and DTI sequences were acquired and analyzed using VBM, SBM and tract-based spatial statistics. No significant alterations of gray matter (GM) volume, cortical thickness, cortical gyrification, sulcus depth and white-matter tract integrity could be observed. However, migraineurs displayed decreased white matter (WM) volume in the left superior longitudinal fasciculus. Second, a systematic review of the literature employing VBM, SBM and DTI was conducted to investigate brain anatomy in migraine. Meta-analysis was performed using Seed-based d Mapping via permutation of subject images (SDM-PSI) on GM volume, WM volume and cortical thickness data. Alterations of GM volume, WM volume, cortical thickness or white-matter tract integrity were reported in 72%, 50%, 56% and 33% of published studies respectively. Spatial distribution and direction of the disclosed effects were highly inconsistent across studies. The SDM-PSI analysis revealed neither significant decrease nor significant increase of GM volume, WM volume or cortical thickness in migraine. Overall there is to this day no strong evidence of specific brain anatomical alterations reliably associated to migraine. Possible explanations of this conflicting literature are discussed. Trial registration number: NCT02791997, registrated February 6th, 2015.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33606142&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;33606142&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1007&#x2F;s10548-021-00824-6&gt;10.1007&#x2F;s10548-021-00824-6&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33606142&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null},{"article_id":1,"discovery_date":"2018-11-01","title":"COVID-19, HHV6 and MOG antibody: A perfect storm","summary":"&lt;div&gt;&lt;p style&#x3D;&quot;color: #4aa564;&quot;&gt;J Neuroimmunol. 2021 Feb 12;353:577521. doi: 10.1016&#x2F;j.jneuroim.2021.577521. Online ahead of print.&lt;&#x2F;p&gt;&lt;p&gt;&lt;b&gt;ABSTRACT&lt;&#x2F;b&gt;&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;BACKGROUND: Serious neurological complications of SARS-CoV-2 are increasingly being recognized.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CASE: We report a novel case of HHV6 myelitis with parainfectious MOG-IgG in the setting of COVID-19-induced lymphopenia and hypogammaglobulinemia. The patient experienced complete neurological recovery with gancyclovir, high dose corticosteroids, and plasma exchange. To our knowledge, this is the first case of HHV6 reactivation in the central nervous system in the setting of COVID19 infection and the first case of MOG-IgG myelitis in the setting of SARS-CoV-2 and HHV6 coinfection.&lt;&#x2F;p&gt;&lt;p xmlns:xlink&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1999&#x2F;xlink&quot; xmlns:mml&#x3D;&quot;http:&#x2F;&#x2F;www.w3.org&#x2F;1998&#x2F;Math&#x2F;MathML&quot; xmlns:p1&#x3D;&quot;http:&#x2F;&#x2F;pubmed.gov&#x2F;pub-one&quot;&gt;CONCLUSION: Patients with neurological manifestations in the setting of COVID19-related immunodeficiency should be tested for opportunistic infections including HHV6. Viral infection is a known trigger for MOG-IgG and therefore this antibody should be checked in patients with SARS-CoV-2 associated demyelination.&lt;&#x2F;p&gt;&lt;p style&#x3D;&quot;color: lightgray&quot;&gt;PMID:&lt;a href&#x3D;&quot;https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33607505&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2&quot;&gt;33607505&lt;&#x2F;a&gt; | DOI:&lt;a href&#x3D;https:&#x2F;&#x2F;doi.org&#x2F;10.1016&#x2F;j.jneuroim.2021.577521&gt;10.1016&#x2F;j.jneuroim.2021.577521&lt;&#x2F;a&gt;&lt;&#x2F;p&gt;&lt;&#x2F;div&gt;","link":"https:&#x2F;&#x2F;pubmed.ncbi.nlm.nih.gov&#x2F;33607505&#x2F;?utm_source&#x3D;Other&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc&#x3D;20210216052009&amp;ff&#x3D;20210220104920&amp;v&#x3D;2.14.2","published_date":"","source":"pubmed","relevant":null,"table_constraints":null}]